Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland

被引:0
作者
Vesikansa, Aino [1 ]
Mehtala, Juha [1 ]
Aaltonen, Jaakko [2 ]
Konttinen, Riikka [2 ]
Tasanen, Kaisa [3 ,4 ]
Huilaja, Laura [3 ,4 ]
机构
[1] MedEngine Oy, Helsinki, Finland
[2] AbbVie Oy, Helsinki, Finland
[3] Univ Oulu, Oulu Univ Hosp, PEDEGO Res Unit, Dept Dermatol, Oulu, Finland
[4] Univ Oulu, Oulu Univ Hosp, Med Res Ctr, PEDEGO Res Unit, Oulu, Finland
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
biologic; biological treatment; healthcare resource utilization; oral immunosuppressants; Psoriasis vulgaris; real-world evidence; SEVERE PLAQUE PSORIASIS; ECONOMIC BURDEN; MODERATE; COSTS; COMORBIDITY; PREVALENCE; ADHERENCE; THERAPIES; SURVIVAL; COHORT;
D O I
10.3389/fimmu.2024.1374829
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction and aim Psoriasis vulgaris is associated with a significant healthcare burden, which increases over time as the disease progresses. The aim of this retrospective, population-based registry study was to characterize healthcare resource utilization (HCRU) in patients with psoriasis using biologics and oral immunosuppressants (conventionals) in Finland.Materials and methods The study cohort included all patients with a diagnosis of psoriasis vulgaris in the secondary healthcare setting between 2012-2018, who initiated a biologic (n=1,297) or conventional (n=4,753) treatment between 2013-2017. Data on primary and secondary HCRU were collected from nationwide healthcare registries.Results The results indicated a remarkable decrease in contacts with a dermatologist after the treatment initiation among patients starting biologic (mean annual number of contacts 5.4 per person before and 2.3 after the initiation), but not conventional (3.3 and 3.2) treatment. For conventional starters there was a high level of contacts with a dermatologist surrounding times of treatment switching, which was not observed for biologic starters.Conclusion Overall, primary and other secondary care contacts did not decrease after the initiation or switch of treatment. The results highlight the importance of thorough consideration of the most optimal treatment alternatives, considering the overall disease burden to patients and healthcare systems.
引用
收藏
页数:9
相关论文
共 31 条
  • [1] Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis
    Al Sawah, Sarah
    Foster, Shonda A.
    Goldblum, Orin M.
    Malatestinic, William N.
    Zhu, Baojin
    Shi, Nianwen
    Song, Xue
    Feldman, Steven R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 982 - 990
  • [2] [Anonymous], 2023, Current care guidelines
  • [3] [Anonymous], 2021, TERVEYDEN JA HYVINVO
  • [4] Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
    Armstrong, April W.
    Read, Charlotte
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19): : 1945 - 1960
  • [5] Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
    Armstrong, April W.
    Foster, Shonda A.
    Comer, Brian S.
    Lin, Chen-Yen
    Malatestinic, William
    Burge, Russel
    Goldblum, Orin
    [J]. BMC DERMATOLOGY, 2018, 18
  • [6] Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany
    Augustin, Matthias
    Reich, Kristian
    Glaeske, Gerd
    Schaefer, Ines
    Radtke, Marc
    [J]. ACTA DERMATO-VENEREOLOGICA, 2010, 90 (02) : 147 - 151
  • [7] Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis
    Bhosle, Monali J.
    Feldman, Steven R.
    Camacho, Fabian T.
    Whitmire, J. Timothy
    Nahata, Milap C.
    Balkrishnan, Rajesh
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2006, 17 (05) : 294 - 301
  • [8] Economic Burden of Psoriasis in the United States A Systematic Review
    Brezinski, Elizabeth A.
    Dhillon, Jaskaran S.
    Armstrong, April W.
    [J]. JAMA DERMATOLOGY, 2015, 151 (06) : 651 - 658
  • [9] Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
    Doshi, Jalpa A.
    Takeshita, Junko
    Pinto, Lionel
    Li, Penxiang
    Yu, Xinyan
    Rao, Preethi
    Viswanathan, Hema N.
    Gelfand, Joel M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) : 1057 - U409
  • [10] Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
    Esposti, Luca Degli
    Perrone, Valentina
    Sangiorgi, Diego
    Buda, Stefano
    Andretta, Margherita
    Rossini, Maurizio
    Girolomoni, Giampiero
    [J]. BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 151 - 158